

CONTINUING EDUCATION INFORMATION

Continuing Education credits for Psych Congress are provided by HMP Education. The live activity will take place September 17–21, 2025. If you purchased the Maximum Credit Pass, recorded sessions will be available on demand for viewing until April 21, 2026.

INTENDED LEARNERS

This activity is intended for psychiatrists, primary care physicians, psychologists, nurse practitioners, physician associates/assistants, psychiatric nurses, and other healthcare professionals who seek to improve the care of patients with mental health disorders.

LEARNING OBJECTIVES

After participating in Psych Congress, participants should be better able to:

- Integrate the most current pharmacologic and nonpharmacologic interventions to improve patient outcomes in the acute and long-term management of mental illness
- Utilize new skills and understanding of key strategies, resources, and opportunities available to optimize a career in mental health care
- Analyze emerging clinical and technological research and tools and their current and potential future impact on revolutionizing mental health care

INSTRUCTIONS FOR RECEIVING CREDIT

To be eligible for documentation of credit for each session attended, learners must participate in the activity and complete the session(s) and overall conference evaluations, as well as post-test(s), if applicable. **Participants who complete the evaluation online within 30 days of the conference will receive documentation of credit.** Your certificate may not load if you are accessing it from a smartphone or if your browser settings do not allow a new tab/window to open.

To access evaluations, open the mobile app and select Claim Credit or visit hmpeducation.com/event/25-USPC-101. You will need your registration email address.

STEPS

1. Complete the evaluations of the sessions you participated in.
2. Complete the Conference General Survey to unlock your certificate.
3. Download or print your certificate of credit. If you require multiple certificates, repeat Step 1. Once a certificate has been claimed, physicians and pharmacists may elect for credits to be submitted on their behalf to their boards via additional fields that will appear within the Claim Certificate page. Credits must be submitted through this process to be reported to the American Board of Surgery and the National Association of Boards of Pharmacy.
4. Keep your certificate of credit for your records. You will not receive a certificate by mail.

NOTE: You may claim credit for the live event via the online evaluation until October 21, 2025. After that date if you registered for the Maximum Credit Pass, you may claim credit for the on-demand recordings via the online evaluation until May 21, 2026.

ACCREDITATION



In support of improving patient care, HMP Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Note: This statement is not an indication of approved credits. Please see below for full accreditation details, including credit types and totals, for this activity.

CREDIT DESIGNATION STATEMENTS

PHYSICIANS

Live

HMP Education designates this live activity for 27.75 *AMA PRA Category 1 Credits™*, with a possible additional 3.00 *AMA PRA Category 1 Credits™* for participation in a preconference. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

On Demand

HMP Education designates this enduring activity for a maximum of 93.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PHYSICIAN ASSOCIATES/ASSISTANTS

Live



HMP Education has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This live activity is designated for 27.75 AAPA Category 1 Credits, with a possible additional 3.0 AAPA Category 1 Credits for participation in a preconference. PAs should claim only the credit commensurate with the extent of their participation.

On Demand

HMP Education has been authorized by the American Academy of Physician Assistants (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This enduring activity is designated for 93.75 AAPA Category 1 Credits. PAs should claim only the credit commensurate with the extent of their participation. Approval valid until May 21, 2026.

PHARMACISTS

Live

This live, knowledge-based activity (Universal Activity Number JA0006201-0000-25-034-L01-P) has been approved for 27.75 contact hours (2.75 CEUs), with a possible additional 3.00 contact hours (0.30 CEUs) for participation in a preconference.

On Demand

This enduring, knowledge-based activity (Universal Activity Number JA0006201-0000-25-035-H01-P) has been approved for 93.75 contact hours (9.375 CEUs).

Note: The certificate is not the official record of your participation in the activity. The official record of credit will be the information in the CPE Monitor system. **Following ACPE Policy, credit must be transmitted to NABP through CPE Monitor within 60 days from the date you complete this CPE activity.**

PHARMACOTHERAPEUTICS

Live

This live activity will award up to 19 pharmacotherapeutic contact hours.

On Demand

This enduring activity will award up to 35.75 pharmacotherapeutic contact hours.

NURSES

Live

This continuing nursing education live activity awards 27.75 contact hours, with a possible additional 3.0 contact hours for participation in a preconference. Provider approved by the California Board of Registered Nursing, Provider #18006, for 30.75 contact hours.

On Demand

This continuing nursing education enduring activity awards 93.75 contact hours. Provider approved by the California Board of Registered Nursing, Provider #18006, for 93.75 contact hours.

NURSE PRACTITIONERS

American Academy of Nurse Practitioners National Certification Program accepts *AMA PRA Category 1 Credit™* from organizations accredited by the ACCME.

PSYCHOLOGISTS

Live



Continuing Education (CE) credits for psychologists are provided through the cosponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This live activity awards 27.75 continuing education credits, with a possible additional 3.0 continuing education credits for participation in a preconference.

On Demand

Continuing Education (CE) credits for psychologists are provided through the cosponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. This enduring activity awards 93.75 continuing education credits.

SOCIAL WORK

Live



As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. HMP Education maintains responsibility for this course. Social workers completing this live activity receive 27.75 general continuing education credits, with a possible additional 3.0 general continuing education credits for participation in a preconference.

On Demand

As a Jointly Accredited Organization, HMP Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. HMP Education maintains responsibility for this course. Social workers completing this enduring activity receive 93.75 general continuing education credits.

MARRIAGE AND FAMILY THERAPY

Live

Psych Congress meets the qualifications for 27.75 hours of continuing education credit, with a possible additional 3.0 hours of continuing education credit for participation in a preconference for LMFIs, LCSWs, LPCs, and/or LEPs as required by the California Board of Behavioral Sciences.

As a Jointly Accredited Organization, HMP Education is approved by the American Psychological Association to sponsor continuing education for psychologists. The APA preapproves New Jersey, Connecticut, Delaware, Rhode Island, South Dakota, and Washington DC, for Marriage and Family Therapy credit. HMP Education has received pre-approval for this live conference from the following marriage and family boards:

New York: HMP Education is recognized by the New York State Education Department's State Board for Mental Health Practitioners as an approved provider of continuing education for licensed marriage and family therapists #MFT-0085.

California: HMP Education is approved by the California Association of Marriage and Family Therapists to sponsor continuing education for Psych Congress 2025. HMP Education maintains responsibility for this program/course and its content. Provider #147376

INTERNATIONAL RECOGNITION

Visit [this link](#) for countries and regions that have reciprocity with the ACCME.

Visit [this link](#) for additional countries that accept ACCME-accredited continuing medical education (CME).

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

HMP Education is an independent provider of continuing medical education. HMP Education has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

In accordance with our disclosure policies, HMP Education is committed to ensuring balance, independence, objectivity, and scientific rigor for all accredited continuing education. These policies include assigning relevance to, and mitigating, all perceived or real relevant financial relationships (conflicts of interest) between any individual with control over the content and any ineligible company (commercial interest) as defined by an ineligible company (commercial interest) as defined by the ACCME and CPME.

Any individual with control over accredited content, including planner, faculty, and reviewer, is required to globally disclose:

1. Individual relationship(s) or lack thereof, and its nature, with any/all ineligible company; and
2. Any investigational, off-label, or non-FDA approved content or discussion

HMP Education has reviewed these disclosures, assigned relevance based on the relationship and scope of content, and identified those with the potential to compromise the goals and educational integrity of the education. Relevant relationships, or lack thereof, are shared with the learner.

Education has been independently peer-reviewed to validate content, mitigate identified financial relationships (conflicts of interest), and ensure that:

1. All recommendations involving clinical medicine are based on evidence that is accepted within the medical profession as adequate justification for their indications and contraindications in the care of patients.
2. All scientific research referred to, reported, or used in accredited continuing education in support or justification of a patient care recommendation conforms to generally accepted standards of experimental design, data collection, and analysis.
3. Content is appropriate, fair and balanced, unbiased, referenced, and nonpromotional.

All relevant financial relationships have been mitigated.

FACULTY

For a complete listing of faculty affiliations, please view the printed Conference Guide distributed at the meeting.

Speaker disclosures will be made prior to the start of each session.

The faculty have reported the following:

Elias Aboujaoude, MD, MA: Advisory Board—MediKarma (ended, May 1, 2024); Stockholder—Big Health

Marc E. Agronin, MD: Grant/Research Support—Alzheon, Bristol Myers Squibb, Eli Lilly, IGC Pharma, Noah Pharmaceuticals, Suvien; Speakers Bureau—Otsuka

Brittany B. Albright, MD, MPH: Advisory Board—Bristol Myers Squibb, Johnson & Johnson; Consultant—AbbVie, Axsome, Johnson & Johnson, Osmind, Precision Genetics; Speakers Bureau—AbbVie, Alkermes, Axsome, Johnson & Johnson

Jacques Ambrose, MD, MPH, MBA, FAPA: Consultant—Johnson & Johnson

James Appio, PharmD: Employee/Owner—Bristol Myers Squibb

Michael Asbach, DMSc, PA-C: Advisory Board—Alkermes, Bristol Myers Squibb, Intra-Cellular Therapies; Consultant—Axsome, Biogen, Bristol Myers Squibb, Janssen, Neurocrine; Speakers Bureau—AbbVie, Avanir (ended), Axsome, Intra-Cellular Therapies, Janssen, Neurocrine, Otsuka

Rebecca K. Barbee, MSPAS, PA-C, CAQ-Psychiatry: Advisory Board—Axsome Therapeutics; Speakers Bureau—Alkermes PLC

Julie A. Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN: Advisory Board—Alkermes, Bristol Myers Squibb, Otsuka, Supernus Pharmaceuticals; Consultant—Otsuka

Robin Carhart-Harris, PhD: Consultant—Mindstate, Osmind, Otsuka, Tryp Therapeutics

Steven R. Chan, MD, MBA, FAPA, FAMA: Consultant—NODE Health; Employee/Owner—AsynchHealth; Major Stockholder—AsynchHealth, Doximity; Other Financial or Material Support—AsynchHealth, Doximity, Orbit Health (ended)

Craig Chepke, MD, DFAPA: Advisory Board—AbbVie, Acadia, Alkermes, Axsome, Biogen, Bristol Myers Squibb, Corium, Idorsia, Intracellular, Johnson & Johnson, Lundbeck, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Acadia, Alkermes, Axsome, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intracellular, Johnson & Johnson, Lundbeck, MedinCell, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Supernus, Teva; Grant Research/Support—Acadia, Axsome, Harmony, Neurocrine, Teva; Speakers Bureau—AbbVie, Acadia, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intracellular, Johnson & Johnson, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sumitomo, Teva

Leslie L. Citrome, MD, MPH: Consultant—AbbVie/Allergan, Acadia, Adamas, Alkermes, Angelini, Astellas, Avanir, Axsome, Biogen, BioXcel, Bristol-Myers Squibb, Boehringer Ingelheim, Cadent Therapeutics, Cerevel, Clinilabs, COMPASS, Delpor, Eisai, Enteris BioPharma, HLS Therapeutics, Idorsia, INmune Bio, Impel, Intra-Cellular Therapies, Janssen, Karuna, Lundbeck, Luye, Lyndra, MapLight, Marvin, Medavante-ProPhase, Merck, Mitsubishi-Tanabe Pharma, Neumora, Neurocrine, Neurelis, Noema, Novartis, Noven, Otsuka, Ovid, Praxis, Recordati, Relmada, Reviva, Sage, Sumitomo/Sunovion, Supernus, Teva, University of Arizona, Vanda, Wells Fargo, and one-off ad hoc consulting for individuals/entities conducting marketing, commercial, or scientific scoping research; Royalties/Publishing Income—Taylor & Francis (Editor-in-Chief, *Current Medical Research and Opinion*, 2022 to date), Wiley (Editor-in-Chief, *International Journal of Clinical Practice*, through end 2019), UpToDate (reviewer), Springer Healthcare (book), Elsevier (Topic Editor, Psychiatry, Clinical Therapeutics); Speakers Bureau—AbbVie/Allergan, Acadia, Alkermes, Angelini, Axsome, BioXcel, Bristol-Myers Squibb, Eisai, Idorsia, Intra-Cellular Therapies, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Recordati, Sage, Sunovion, Takeda, Teva, Vanda, and CME activities organized by medical education companies such as Medscape, NACCME, NEI, Vindico, and Universities and Professional Organizations/Societies; Stocks (small number of shares of common stock)—Bristol-Myers Squibb, Eli Lilly, J&J, Merck, Pfizer purchased > 10 years ago; Stock Options—Reviva

Christoph U. Correll, MD: Advisory Board—AbbVie, Alkermes, Allergan, Angelini, BMS, Boehringer Ingelheim, Bristol-Myers Squibb, Cerevel, Compass, Gedeon Richter, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, Merck, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Rovi, Sage, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatrix; Consultant—AbbVie, Alkermes, Allergan, Angelini, Autobahn, Boehringer Ingelheim, Bristol-Myers Squibb, Cerevel, Compass, Denovo, Eli Lilly, Gedeon Richter, GH, IntraCellular Therapies, Janssen/J&J, Karuna, Kuleon Biosciences, LB Pharma, Lundbeck, MedInCell, Medlink, Merck, Mindpax, Neuraxpharm, Neurelis, Neurocrine, Newron, Novo Nordisk, Otsuka, Recordati, Relmada, Reviva, Rovi, Sage, Seqirus, Life Science, Sunovion, Supernus, Teva, Vertex, Viatrix; Grant/Research Support—Boehringer Ingelheim, Janssen, Takeda

Erin C. Crown, MHS, PA-C, CAQ-Psychiatry: Consultant—AbbVie, Axsome, Bristol Myers Squibb, Intracellular, Janssen, Lundbeck, Neurocrine, Otsuka, Supernus; Speakers Bureau—Axsome, Bristol Myers Squibb, Janssen, Intracellular, Lundbeck, Neurocrine, Otsuka, Supernus

Andrew J. Cutler, MD: Advisory Board—AbbVie Inc, Alkermes PLC, Axsome Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol Myers Squibb, Corium, Intra-Cellular Therapies, J&J Innovative Medicine, LivoNova, Lundbeck, Neumora, Neurocrine, Otsuka, Supernus Pharmaceuticals, Teva, Tris Pharma, Vanda Pharmaceuticals, VistaGen Therapeutics; Consultant—4M Therapeutics, AbbVie Inc, Alfasigma, Alkermes PLC, Autobahn Therapeutics, Axsome Therapeutics, Boehringer Ingelheim Pharmaceuticals, Bristol Myers Squibb, Collegium Pharma, Corium, Delpor, Intra-Cellular Therapies, J&J Innovative Medicine, Jazz Pharma, Knight Therapeutics, LivoNova, Lundbeck, Luye Pharma, Maplight Therapeutics, Neumora, Neurocrine, Noven, Otsuka, Supernus Pharmaceuticals, Teva, Tris Pharma, Vanda Pharmaceuticals, VistaGen Therapeutics; Other Financial or Material Support—4M Therapeutics; Speakers Bureau—AbbVie Inc, Alfasigma, Alkermes PLC, Axsome Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol Myers Squibb, Collegium Pharma, Corium, Intra-Cellular Therapies, J&J Innovative Medicine, Knight Therapeutics, Lundbeck, Luye Pharma, Neurocrine, Noven, Otsuka, Supernus Pharmaceuticals, Teva, Tris Pharma, Vanda Pharmaceuticals

Kristian Dambrino, DNP, PMHNP-BC: Advisory Board—Johnson & Johnson; Consultant—Axsome Therapeutics, Neurocrine Biosciences; Speakers Bureau—Axsome Therapeutics, Bristol-Myers Squibb, Neurocrine Biosciences

Jami Earnest, PharmD, BCPP: Employee/Owner—Biogen/Supernus, Supernus Pharmaceuticals; Major Stockholder—Johnson & Johnson; Other Financial or Material Support—Alkermes PLC, Biogen/Supernus, Johnson & Johnson

Justin Faden, DO: Speakers Bureau—Bristol-Myers Squibb, Luye Pharma Group, Ltd.

Erin Ferries, PhD, MPH: Employee/Owner—Mind Medicine (MindMed)

Philip Gehrman, PhD, CBSM, FAASM: Grant/Research Support—Jazz Pharma, Merck & Co., Inc. (ended)

Joseph F. Goldberg, MD: Advisory Board—Luye Pharma Group, Ltd (ended December 31, 2024), Neumora; Consultant—AbbVie, Alkermes, Alvogen, BMS, Genomind (ended December 31, 2024), Otsuka; Speakers Bureau—BMS, ITCI; Royalties/Patent Income—American Psychiatric Publishing, Cambridge University Press

James Greenblatt, MD: Employee/Owner—Psychiatry Redefined; Royalties/Patent Income—Psychiatry Redefined; Speakers Bureau—Pure Encapsulations

Boris D. Heifets, MD, PhD: Advisory Board—Journey Clinical, Osmind; Consultant—Arcadia Medicine Inc., Vida Ventures LLC, Tactogen Inc

Amber Hoberg, PMHNP-BC: Advisory Board—Bristol Myers Squibb; Consultant—Bristol Myers Squibb; Speakers Bureau—Bristol Myers Squibb

Mike Hogan, PharmD: Employee/Owner—Otsuka Pharmaceutical Development & Commercialization Inc

Elena I. Ivleva, MD, PhD: Advisory Board—Alkermes, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Janssen Pharmaceuticals, Karuna Therapeutics; Grant/Research Support—APA, BBRF/NARSAD, Boehringer Ingelheim Pharmaceuticals Inc, Neurocrine Biosciences, Inc, NIH/NIMH

Jessica Jackson, PhD: Advisory Board—AugMend Health; Consultant—AugMend Health; Employee/Owner—Mental Health America

Richard Jackson, MD: Consultant—AbbVie, Alkermes, Axsome, BMS, Janssen, Lundbeck, Noven, Otsuka, Supernus, Vanda; Research—Cingulate Therapeutics, Intra-Cellular Therapies, MapLight, Neumora, Otsuka, Relmada, Sirtsei, Supernus Pharmaceuticals, Suven Life Sciences, Teva, Vistagen; Speakers Bureau—AbbVie, Alkermes, Axsome, BMS, Janssen, Lundbeck, Noven, Otsuka, Supernus, Vanda

Rakesh Jain, MD, MPH: Advisory Board—Adamas, Alkermes, Corium, Eisai, Indivior, Intra-Cellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Supernus, Takeda, Teva, Tris Pharmaceuticals; Consultant—AbbVie (Allergan), Acadia, Adamas, Alfasigma USA Inc., Axsome, Corium, Cingulate Therapeutics, Eisai, Evidera, Impel NeuroPharma, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine Biosciences, Osmotica, Otsuka, Pamlab, Pfizer, Sage Therapeutics, Shire, Sunovion, Supernus, Takeda, Teva; Grant/Research Support—AbbVie (Allergan), Lilly, Lundbeck, Otsuka, Pfizer, Shire, Takeda; Speakers Bureau—AbbVie (Allergan), Alkermes, Axsome, Corium, Eisai, Indivior, Intracellular Therapies, Ironshore Pharmaceuticals, Janssen, Lilly, Lundbeck, Merck, Neos Therapeutics, Neurocrine, Otsuka, Pamlab, Pfizer, Shire, Sunovion, Takeda, Teva, Tris Pharmaceuticals

Sandra Jain, MA, PsyD, LPC: Advisory Board—Eli Lilly, Otsuka, Pamlab; Consultant—Eli Lilly, Otsuka, Pamlab, Sage Therapeutics, Sunovion; Speakers Bureau—Eli Lilly, Otsuka

Manish K. Jha, MBBS: Consultant—IQVIA Ltd., Worldwide Clinical Trials; Other Financial Material Support—Vicore (ended April 18, 2025)

Brooke Kempf, PMHNP-BC: Advisory Board—Alkermes, Axsome, Bristol Myers Squibb, Johnson and Johnson, Janssen, Intracellular, Teva; Speakers Bureau—Alkermes, Axsome, Bristol Myers Squibb, Johnson and Johnson, Janssen, Intracellular, Teva

Mahwish Khan, PharmD, RPh: Employee/Owner—Noven Pharmaceuticals

Andrew D. Krystal, MD: Consultant—AbbVie, Axsome Therapeutics, Big Health, Eisai, Evecxia, Harmony Biosciences, Idorsia, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Neumora, Neurawell, Neurocrine Biosciences, Otsuka Pharmaceuticals, Sage, Takeda; Grant/Research Support—Alkermes, Attune, Axsome Therapeutics, Eisai, Harmony Biosciences, Janssen Pharmaceuticals, Neumora, Neurocrine Biosciences, Reveal Biosensors, National Institutes of Health, Ray and Dagmar Dolby Family Fund, Weill Institute for Neurosciences; Stockholder—Big-Health, Neurawell

Kristin Lasseter, MD: Consultant—Hims

Michael Martin, MD, MBA: Employee/Owner—Takeda Pharmaceuticals U.S.A.

Desiree Matthews, PMHNP-BC: Advisory Board—AbbVie, Alkermes, Biogen/Sage, Bristol Myers Squibb, Johnson & Johnson, Teva Pharmaceuticals; Consultant—AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Indivior, Johnson & Johnson, Neurocrine Biosciences, Otsuka Pharmaceuticals, Teva Pharmaceuticals; Speakers Bureau—AbbVie, Axsome, Bristol Myers Squibb, Intracellular Therapeutics, Johnson & Johnson, Lundbeck, Luye, Neurocrine Biosciences, Otsuka Pharmaceuticals, Teva Pharmaceuticals

Greg Mattingly, MD: Consultant—AbbVie, Acadia, Akilli, Alkermes, Angelini, Axsome, Aytu, Biogen, BMS, Boehringer Ingelheim, Cerevel, Corium, Eisai, Intracellular, Ironshore, Johnson & Johnson, Liva Nova, Lumos Labs, Lundbeck, Neurocrine, Noven, Otsuka, Redax, Relmada, Revibe, Roche, Sage, Sirona, Sky Therapeutics, Sunovion, Supernus, Takeda, Teva, and Tris Pharma; Research—AbbVie, Acadia, Alkermes, Akilli, Alto Therapeutics, Avansir, Axsome, BMS, Boehringer Ingelheim, Cingulate, Click Therapeutics, Corium, Emalex, Idorsia, Intracellular, Johnson & Johnson, Karuna, Lumos Labs, Medgenics, Neurocrine, NLS Pharma, Redax, Relmada, Roche, Sage, Sirtsei, Sumitomo, Sunovion, Supernus, Takeda, and Teva; Speakers Bureau—AbbVie, Alkermes, Angelini, Axsome, BMS, Corium, Intracellular, Ironshore, Johnson & Johnson, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, and Tris Pharma

Johnathan M. Meyer, MD: Consultant—AbbVie, Alkermes, Axsome, BMS, ITCI, Neurocrine, Teva; Speakers Bureau—AbbVie, Alkermes, Axsome, BMS, ITCI, Neurocrine, Teva

Emmanuel Mignot, MD, PhD: Advisory Board—Centessa, Jazz Pharmaceuticals, Takeda; Grant/Research Support—Alkermes, Avadel, Beacon, Eisai, Harmony, Idorsia, Jazz Pharmaceuticals, Sunovion, Takeda, Vanda

Michael Miller, MD, DLFAPA, DFASAM: Advisory Board—BestNotes, JSI (ended December 31, 2024), Peterson Health Technology Institute; Speakers Bureau—Alkermes, BestNotes

Chelsie Monroe, APN, PMHNP-BC: Advisory Board—AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Neurocrine Biosciences, Otsuka, Teva Pharmaceuticals; Speakers Bureau—AbbVie, Alkermes, Axsome, Bristol Myers Squibb, Neurocrine Biosciences, Otsuka, Teva Pharmaceuticals

Anne Marie Morse, DO, FAASM: Advisory Board—Alkermes PLC, Avadel Pharmaceuticals, FloraWorks, Harmony Biosciences, Jazz Pharma, Neurahealth, openevidence, Takeda Pharmaceuticals U.S.A.; Consultant—Alkermes PLC, Avadel Pharmaceuticals, Harmony Biosciences, Jazz Pharma; Grant/Research Support—Alkermes PLC, Avadel Pharmaceuticals, Jazz Pharma, Takeda Pharmaceuticals U.S.A.; Speakers Bureau—Avadel Pharmaceuticals, Axsome Therapeutics, Harmony Biosciences

Moushumi Mukerji, MSN, PMHNP-BC, CNM: Advisory Board—Sage-Biogen (ended 10/19/2023); Consultant—AbbVie Inc

Nadia Nabulsi, MPH, PHD: Employee/Owner—AbbVie Inc

Hara Oyedeji, APRN, PMHNP-BC, MSEd: Advisory Board—Alkermes PLC, BMS; Consultant—Alkermes PLC; Speakers Bureau—Alkermes PLC, BMS, Intracellular, Neurocrine Biosciences Inc, Otsuka Pharmaceuticals, Teva Pharmaceuticals

Hemagni R. Panchmatia, Msc: Employee/Owner—Alkermes, Inc.

Andrew D. Penn, MS, PMHNP-BC: Advisory Board—Alkermes PLC, NACCME, Osmind, Otsuka, Tactogen; Consultant—1440 Foundation, Alkermes PLC, Board of Psychedelic Medicine and Therapies (ended July 1, 2024), California Institute of Integral Studies, Luciem, Mind Medicine (MindMed) Inc, NACCME, Otsuka; Grant/Research Support—Filament

David T. Plante, MD, PhD: Advisory Board—Alkermes PLC, Apnimed, Centessa, Harmony Biosciences, Jazz Pharma, Takeda Pharmaceuticals U.S.A.; Consultant—Aduitum Bio (ended), Alkermes PLC, Centessa, Harmony Biosciences, Jazz Pharma, Takeda Pharmaceuticals U.S.A., Teva Pharmaceuticals Australia (ended)

Arwen Podesta, MD: Advisory Board—AbbVie Inc, Indivior Pharmaceuticals, JAYMAC, Otsuka Pharmaceutical Development & Commercialization Inc, SageSurfer; Other Financial or Material Support—Molecular World Health, Psychiatry Redefined; Speakers Bureau—AbbVie Inc, Alkermes PLC, Braeburn, Indivior Pharmaceuticals

Charles L. Raison, MD: Consultant—Otsuka Pharmaceutical Development & Commercialization Inc, Usona Institute

Eiry Roberts, MD: Employee/Owner—Neurocrine Biosciences, Inc.

Gerard Sanacora, MD, PhD: Advisory Board—Biohaven Pharmaceuticals, Boehringer Ingelheim International GmbH, Clexio Biosciences, Douglas Pharmaceuticals, Embark (ended March 1, 2025), Freedom Biosciences, Gilgamesh, Holmus, Newelos, Relmada Therapeutics, Inc., Seaport Pharmaceuticals, Tetricus, Transcend Therapeutics; Consultant—AbbVie Inc, Actinogen Medical, Alto Neuroscience Inc, Atai, Axsome Therapeutics, Biogen/Sage, Bristol-Myers Squibb, Daiichi Sankyo, Lilly, Merck, Neumora, Neurocrine Biosciences Inc, Novartis, Otsuka Pharmaceutical Development & Commercialization Inc, Seelos Pharmaceuticals, Supernus Pharmaceuticals, Usona Institute; Grant/Research Support—Merck, Usona Institute; Major Stockholder—Biohaven Pharmaceuticals, Freedom Biosciences, Newelos, Tetricus; Royalties/Patent Income—Biohaven Pharmaceuticals, Freedom Biosciences

Lara Shirikjian, DO: Advisory Board—Bristol Myers Squibb; Consultant—Boehringer Ingelheim (ended September 23, 2024); Speakers Bureau—Axsome, Bristol Myers Squibb, Johnson and Johnson

Abhinav Singh, MD, MPH, FAASM: Advisory Board—Axsome Therapeutics, Harmony Biosciences, Jazz Pharmaceuticals, Resmed; Consultant—Jazz Pharmaceuticals; Grant/Research Support—Avadel Pharma; Speakers Bureau—Axsome Therapeutics, Eli Lilly & Company, Harmony Biosciences, Jazz Pharmaceuticals

Stephen M. Stahl, MD, PhD, DSc (Hon.): Consultant—Acadia, AbbVie/Allergan, Alkermes, Altus, Axsome, Bristol Myers Squibb, Clearview, Clexio, Compass Pathways, Delix, Done, Gate Neurosciences, Intra-Cellular Therapies, Janssen, Karuna Therapeutics, Longboard, LivaNova, Lundbeck, Neurocrine Biosciences, Neurawell, Otsuka, Relmada Therapeutics, Sage Therapeutics, Supernus, Tonix, Tris Pharma, Validus, Vanda; Major Stockholder—Delix, Genomind, Lipidio, Neurawell; Research/Grant Support—Acadia, Allergan/AbbVie, Boehringer Ingelheim, Daiichi Sankyo, Brazil Eisai, Eli Lilly, Intra-Cellular Therapies, Ironshore, Neurocrine, Otsuka, Pear Therapeutics, Sage, Shire Sunovion, Supernus, Torrent; Speakers Bureau—AbbVie/Allergan, Bristol Myers Squibb, Intra-Cellular Therapies, Lundbeck

Murray B. Stein, MD, MPH: Consultant—atai Life Sciences, BigHealth, Biogen, Bionomics, Boehringer Ingelheim, EmpowerPharm (ended), Engrail Therapeutics, Janssen, Jazz Pharmaceuticals, Karuna Therapeutics, Inc. (ended), Lundbeck A/S, Lykos Therapeutics (ended), Newleas Therapeutics, Otsuka Pharmaceutical Company Ltd., PureTech Health, Roche/Genentech, Seaport Therapeutics, Transcend Therapeutics

Michael E. Thase, MD: Advisory/Consultant—Autobahn Therapeutics, Axsome Therapeutics Inc., Clexio Biosciences, Gerson Lehman, GH Therapeutics, H. Lundbeck, A/S, Janssen Pharmaceuticals Inc., Johnson & Johnson, Luye Pharma Group Ltd., Merck & Company Inc., Object Pharma, Otsuka Pharmaceutical Company Ltd., Pfizer Inc., Sage Pharmaceuticals, Seelos Pharmaceuticals, Takeda Pharmaceutical Company Ltd.; Grant/Research Support—Acadia Inc., Alkermes, Axsome Therapeutics Inc., Intracellular Inc., Janssen Pharmaceuticals Inc., Myriad, National Institute of Mental Health, Otsuka Pharmaceutical Company Ltd., Patient-Centered Outcomes Research Institute (PCORI), Takeda Pharmaceutical Company Ltd.; Royalties—American Psychiatric Foundation, Guilford Publications, Herald House, Kluwer-Wolters, W.W. Norton & Company Inc.

Solome Tibebe: Advisory Board—BeMe Health

Kristi Totten, PhD: Employee/Owner—Azurity Pharmaceuticals

Anne Walker, PhD: Employee/Owner—Lundbeck

Peter J. Weiden, MD: Advisory Board—Alkermes PLC, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Teva; Consultant—AbbVie Inc, Alkermes PLC, Anavex, Boehringer Ingelheim, Delpor, MapLight, Teva, Vanda; Grant/Research Support—Boehringer Ingelheim, Bristol Myers Squibb (BMS), MapLight, Neurocrine, Vanda; Other Financial or Material Support—Delpor; Speakers Bureau—Alkermes PLC, Boehringer Ingelheim, Bristol Myers Squibb (BMS), Neurocrine

Timothy E. Wilens, MD: Consultant—Bay Cove Human Services, Gavin Foundation, US Minor/Major League Baseball, US National Football League; Grant/Research Support—NIH, White Rhino/3D Therapeutics; Other Financial or Material Support—Elsevier Psychiatric Clinics of North America (ADHD), Ironshore Pharmaceuticals (ended December 31, 2023), White Rhino/3D Therapeutics; Owner/Employee—Massachusetts General Hospital; Royalties/Patent Income—Cambridge University Press, Guilford Press, Ironshore Pharmaceuticals (ended December 31, 2023)

Kevin N. Williams, MS, MPAS, PA-C: Advisory Board—Biogen/Sage, Myriad, Neurocrine, Supernus Pharmaceuticals, Teva Pharmaceuticals; Speakers Bureau—AbbVie, Alkermes, Myriad, Neurocrine, Teva Pharmaceuticals

W. Christopher Winter, MD, DABSM, DABPN, FAASM: Advisory Board—Avadel Pharma, Axsome Therapeutics, Harmony Biosciences, Jazz Pharma; Consultant—Avadel Pharma, Axsome Therapeutics, Harmony Biosciences, Jazz Pharma; Speakers Bureau—Avadel Pharma, Axsome Therapeutics, Harmony Biosciences, Jazz Pharma

Joel Young, MD: Advisory Board—Collegium Pharmaceutical; Consultant—Collegium Pharmaceutical; Grant/Research Support—Collegium Pharmaceutical, Lumos Pharma (ended); Speakers Bureau—Intra-Cellular Therapies

Mark Zimmerman, MD: Advisory Board—Intracellular Therapeutics; Employee/Owner—Psych Product Press; Speakers Bureau—Intracellular Therapeutics

Nishath Ali, MD; Lydia Bartholow, DNP, PMHNP, CARN-AP, FIAAN; Nadejda Bespalova, MD; Jennifer Brashear; Lloyd Briggery; Scott Burke; Alberto Carrara, LC; Taylor Delanko; Benji Faden; Michele Galiotta, PhD; Meredith Gansner, MD; Laney Geismar; Paul E.A. Glaser, MD, PhD; Nichole Goble; Armen Goenjian, MD; Jill Harkavy-Friedman, PhD; Nichelle Haynes, DO; Karen Horst, MD; Nick Hunter; P. Butler Ives; Nadia Johnson, PhD; Edward Kaftarian, MD; Jodi Koehn-Pike; James Lock, MD, PhD; Kristin L. MacGregor, PhD; Viktoriya Magid, PhD; Kelly Overdorf; Avani Patel, MD, MHA; Helen Peterson; William M. Sauv , MD; Katherine Shear, MD; Karen Soropulova; Ashley H. VanDercar, MD, JD; Vanessa Joy Walker, MA, MPH Candidate, CPC; Katherine Warburton, DO; Denise Wilfley, PhD; and Jonathan R. Williams, DNP, PMHNP-BC, CARN-AP, have no financial relationships to disclose.

CLINICAL REVIEWER

Craig Chepke, MD, DFAPA

Adjunct Associate Professor of Psychiatry
Atrium Health
Medical Director
Excel Psychiatric Associates
Huntersville, North Carolina

Craig Chepke, MD, DFAPA: Advisory Board—AbbVie, Acadia, Alkermes, Axsome, Biogen, Bristol Myers Squibb, Corium, Idorsia, Intracellular, Johnson & Johnson, Lundbeck, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Teva; Advisory Board (Spouse)—Otsuka; Consultant—AbbVie, Acadia, Alkermes, Axsome, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intracellular, Johnson & Johnson, Lundbeck, MedinCell, Moderna, Neurocrine, Noven, Otsuka, Sage, Sumitomo, Supernus, Teva; Grant Research/Support—Acadia, Axsome, Harmony, Neurocrine, Teva; Speakers Bureau—AbbVie, Acadia, Alkermes, Axsome, Boehringer Ingelheim, Bristol Myers Squibb, Corium, Intracellular, Johnson & Johnson, Lundbeck, Merck, Neurocrine, Noven, Otsuka, Sumitomo, Teva

PLANNING COMMITTEE

Planning for this activity was conducted by faculty advisors. To further support the development of the content, additional information regarding professional roles, responsibilities, and teamwork was gathered through survey input from our target audience and/or a comprehensive literature review.

Andrew D. Penn, MS, PMHNP-BC

University of California, San Francisco, School of Nursing
San Francisco, California

Andrew D. Penn, MS, PMHNP-BC: Advisory Board—Alkermes PLC, NACCME, Osmind, Otsuka, Tactogen; Consultant—1440 Foundation, Alkermes PLC, Board of Psychedelic Medicine and Therapies (ended, July 1, 2024), California Institute of Integral Studies, Luciem, Mind Medicine (MindMed) Inc, NACCME, Otsuka; Grant/Research Support—Filament

The planning committee comprises **Julie A. Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN; Steven R. Chan, MD, MBA, FAPA, FAMIA; Craig Chepke, MD, DFAPA; Kali D. Cyrus, MD, MPH; Amber Hoberg, PMHNP-BC; Rakesh Jain, MD, MPH; Sandra Jain, MA, PsyD, LPC; Edward Kaftarian, MD; Brooke Kempf, PMHNP-BC; Samantha Lau, MSN, FNP-BC, PMHNP-BC; Desiree Matthews, PMHNP-BC; Greg Mattingly, MD; Ilan Melnick, MD; Andrew D. Penn, MS, PMHNP-BC; Arwen Podesta, MD; Charles L. Raison, MD; and, from HMP Education, Jordan Bacon, Meaghan Benci, Brielle Calleo, Kristin Ciszewski, Heather Howard, Samantha Joy, Josh Raitt, Randy Robbin, and Andrea Zimmerman, EdD, CHCP.**

NON-ACCREDITED INNOVATION THEATERS

Innovation Theaters are non-accredited presentations. The opinions and recommendations expressed do not necessarily reflect the views of HMP Global. These presentations are not intended or eligible for continuing education (CME/CE) credits. By having your badge scanned or entering the virtual room, you consent to share/receive information with/from the sponsor. Please speak with a Psych Congress representative if you wish to opt out.

Food and beverages are provided by HMP Global. Psych Congress attendees have paid for their meal as part of their conference registration fee.

ADA STATEMENT

HMP Education complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof. Any participant in this educational activity who needs accommodation(s) may [submit a request](#) to the support team.

PRIVACY POLICY

HMP Education protects the privacy of personal and other information regarding participants, educational partners, and joint sponsors. HMP Education and our joint providers will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency. HMP Education maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.

USE OF PROPRIETARY NAMES

This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.

UNAPPROVED AND/OR INVESTIGATIONAL USES OF DRUGS AND DEVICES

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters, or moderators and do not necessarily reflect the opinions of HMP Education.

DISCLAIMERS


The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a provider-patient relationship. Medical advice of any nature should be sought from an individual's own provider.

The opinions expressed in this educational activity are those of the faculty and are not attributable to HMP Global or any of its subsidiaries or affiliates. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.

COMMERCIAL SUPPORT

Psych Congress is supported in part by educational grants from AbbVie Inc.; Alkermes, Inc.; Axsome Therapeutics, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb; Harmony Biosciences; Intra-Cellular Therapies, Inc.; Jazz Pharmaceuticals; Johnson & Johnson; Neurocrine Biosciences, Inc.; Takeda Pharmaceuticals, U.S.A.; and Teva Pharmaceuticals, USA, Inc.

CONTACT US

 For immediate assistance, please explore our [HMP Education Help Center](#) or chat with our Virtual CE Assistant, which can answer most common questions related to claiming credits and the HMP Education website. If you have a question or grievance that cannot be addressed by our Virtual CE assistant and Help Center, please [contact the support team](#). Our accreditation and compliance team will respond to your inquiry within one business day.

PROVIDER STATEMENT



Provided by HMP Education, an HMP Global Company.

Copyright © 2025 by HMP Education. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from HMP Education.